Overall market sentiment has been neutral on AcelRx Pharmaceuticals Inc (ACRX) stock lately. ACRX receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.
AcelRx Pharmaceuticals Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ACRX!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With ACRX Stock Today?
AcelRx Pharmaceuticals Inc (ACRX) stock is unmoved 0% while the S&P 500 is lower by -0.68% as of 10:50 AM on Friday, Sep 17. ACRX is flat $0.00 from the previous closing price of $1.02 on volume of 174,813 shares. Over the past year the S&P 500 has risen 31.25% while ACRX is lower by -20.31%. ACRX lost -$0.36 per share in the over the last 12 months.
To screen for more stocks like AcelRx Pharmaceuticals Inc click here.
More About AcelRx Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States.
Click Here to get the full Stock Report for AcelRx Pharmaceuticals Inc stock.